{"entity":{"id":"avl-101","kind":"drug","name":"AVL-101","aka":[],"tldr":"AVL-101 is an experimental DNA-based therapeutic HPV vaccine from Beijing Xunsheng Biomedical Research, in phase 1 trials for cervical intraepithelial neoplasia grade 2/3 caused by HPV16/18.","summary":"AVL-101 is a DNA-based therapeutic HPV vaccine from Beijing Xunsheng Biomedical Research, with Beijing Anweituo Biomedicine Co., Ltd., subsidiary and trial sponsor as partner. A therapeutic HPV vaccine, not a preventive one: the company says it works by activating cytotoxic T cells that recognise and clear cells carrying HPV16/18, aiming for regression of the lesion and clearance of the virus. Its furthest stage is phase 1, for cervical intraepithelial neoplasia grade 2/3 (CIN2/3) caused by HPV16/18 (a cervical precancer). No clinical trial naming it is registered on ClinicalTrials.gov. Phase 1 site initiation meetings held 9 July 2026 (Tianjin Medical University General Hospital) and 30 July 2026 (Cancer Hospital, Chinese Academy of Medical Sciences), per company news. It has not been shown to work in people.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Beijing Xunsheng Biomedical Research: aeonvital.com","url":"http://www.aeonvital.com/wzxq?article_id=102"},{"label":"Beijing Xunsheng Biomedical Research: aeonvital.com","url":"http://www.aeonvital.com/wzxq?article_id=102"},{"label":"Beijing Xunsheng Biomedical Research: aeonvital.com","url":"http://www.aeonvital.com/page141"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["beijing-xunsheng-biomedical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"AVL-101","modality":"DNA-based therapeutic HPV vaccine","mechanism":"A therapeutic HPV vaccine, not a preventive one: the company says it works by activating cytotoxic T cells that recognise and clear cells carrying HPV16/18, aiming for regression of the lesion and clearance of the virus.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/avl-101/","neighbours":{"company":[{"id":"beijing-xunsheng-biomedical","kind":"company","name":"Beijing Xunsheng Biomedical Research","route":"/companies/beijing-xunsheng-biomedical/"}]}}